The alkylating agent cyclophosphamide has been used in the treatment of multiple myeloma for over 60 years. At low doses, cyclophosphamide also has significant immunomodulatory activity, which can be used to modify the immunosuppressive tumor microenvironment in order to augment responses to existing therapies. Immune-mediated therapies are becoming more widespread in modern approaches to myeloma treatment. In this review, we discuss the effects cyclophosphamide has on the immune system, and how it can be used synergistically with other treatment modalities including the immunomodulatory agents, monoclonal antibodies and cellular therapies.
CITATION STYLE
Swan, D., Gurney, M., Krawczyk, J., Ryan, A. E., & O’Dwyer, M. (2020). Beyond DNA damage: Exploring the immunomodulatory effects of cyclophosphamide in multiple myeloma. HemaSphere. Wolters Kluwer Health. https://doi.org/10.1097/HS9.0000000000000350
Mendeley helps you to discover research relevant for your work.